Medline fire recovery + 340B fight escalates
Supply Chain Pulse — 2026-06-26
Medline says most customer orders are restored after a fire leveled its 1 million-square-foot Tracy, Calif. distribution center — a remarkable recovery turnaround, but one that exposed just how much volume runs through a single node. That vulnerability lands on the same day Eli Lilly's 340B pullback is drawing federal intervention calls from the hospital sector, squeezing supply chain budgets from another direction entirely. Meanwhile, Boston Scientific's $138M Indiana distribution investment and J&J's $1B+ Jacksonville expansion signal that manufacturers are quietly reshoring and redundancy-building in ways that could reshape your sourcing landscape over the next 18 months. If this week has a theme, it's this: the era of assuming your supply base is stable is over — and the smart money is already rebuilding around that reality.
Quick Hits
- FedEx launches dedicated life sciences logistics suite as healthcare becomes a strategic growth pillar, offsetting declining general parcel volume. (Supply Chain Dive)
- Merck KGaA agrees to acquire Bio-Techne for $11.3B in its largest deal since buying Sigma-Aldrich in 2015, expanding its life sciences reagents and tools footprint. (Medical Device Network)
Update: Medline Says Most Customer Orders Restored Following Fire
A fire destroyed Medline's 1 million-square-foot distribution center in Tracy, Calif. — one of the largest medical supply distribution facilities in the country — forcing emergency activation of contingency logistics across its network. The reported restoration of most customer orders is encouraging, but the incident is a live case study in single-point-of-failure risk for any health system running lean inventories. If Medline is a primary distributor for your organization, now is the time to document exactly which SKUs were at risk and stress-test your backup sourcing plans before the next disruption.
Source: Healthcare Purchasing News
Lilly Halts 340B Drug Discounts, Triggers Fury
Eli Lilly has cut off 340B discounts to hospitals, prompting the hospital sector to call on federal authorities to intervene — a significant escalation in the ongoing manufacturer vs. covered entity standoff over the program. For supply chain and pharmacy procurement teams, this is a direct hit to drug spend budgets, particularly for high-cost Lilly products like tirzepatide and insulin that many safety-net and disproportionate share hospitals depend on at 340B pricing. Watch whether CMS or HRSA responds with enforcement action; the outcome will set a precedent for how far other manufacturers will push similar restrictions.
Boston Scientific Announces $138M Investment in Indiana Medical Distribution Center
Boston Scientific is committing $138 million to a new medical device distribution center in Indiana, part of a broader industry trend of manufacturers investing in domestic logistics infrastructure — likely accelerated by tariff pressures and pandemic-era supply lessons. For supply chain leaders, a stronger domestic distribution footprint from a major device manufacturer could mean faster lead times and reduced import exposure on Boston Scientific's cardiology and endoscopy portfolios. It's also a signal worth tracking: when device makers invest this heavily in U.S. distribution, contract and pricing conversations may shift.
Source: Healthcare Purchasing News
Johnson & Johnson Invests Over $1B in Jacksonville Vision Operations
J&J is building a new manufacturing facility in Jacksonville, Fla., as part of its announced $55 billion U.S. investment plan, with this site focused on expanding ACUVUE contact lens production. The move deepens domestic manufacturing capacity for one of the most widely purchased vision care product lines in the country, which could improve supply stability for health systems and optical programs sourcing ACUVUE at volume. It's the second major device-maker domestic expansion in today's brief — a pattern worth noting as you evaluate long-term supplier risk profiles.
Source: Healthcare Purchasing News
Ascension's Next Act: More Surgery Centers, More Deal-Making
Ascension CEO Eduardo Conrado is accelerating ambulatory surgery center expansion into 10 markets, including a partnership with AMSURG — one of the largest ASC operators in the country. For supply chain teams, a rapid ASC build-out at a system of Ascension's scale means new procurement complexity: ASCs run leaner, have less storage, and often require different contracting structures than acute care. If you're not already building an ASC-specific sourcing strategy, Ascension's playbook is a useful forcing function.
How 'Helium-Free' MRI Scanners Are Reshaping Hospital Plans
Helium-free MRI technology — led by systems like Siemens' MAGNETOM Free.Max and GE's newer offerings — is gaining serious traction as health systems like Mayo Clinic look to deploy MRI capacity faster and without the helium supply chain headaches that have plagued radiology departments for years. The practical upside for supply chain: no cryogen management, no helium contracts, and siting flexibility that can reduce facility build costs significantly. Capital equipment planners evaluating MRI replacements or greenfield imaging centers in the next 12–24 months should put helium-free specs on the evaluation checklist now.
How Outpatient Surgery Is Opening the Door for Robot Makers
Distalmotion CEO Greg Roche says the company is gaining ground specifically because health systems are shifting procedures to ASCs — and ASC-optimized robotic platforms are smaller, cheaper, and faster to deploy than traditional hospital-grade surgical robots. This is part of a broader ASC equipment arms race: as Ascension and others aggressively expand ambulatory footprints, device makers are racing to offer platforms that fit the ASC cost and space model. Supply chain and value analysis teams should expect an uptick in robotic surgery proposals tailored to ASC specs over the next 12 months.
Hartford HealthCare Shares Supply Chain Success at Healthcare Supply Chain Tech Summit
HPN's 2026 Supply Chain Department of the Year, Hartford HealthCare, presented its enterprise-wide model at the Healthcare Supply Chain Tech Summit, spotlighting leadership structure, innovation culture, and measurable improvement as the pillars of its recognized performance. For peers looking to benchmark or build the case internally for supply chain investment, Hartford's framework is worth a close look — especially as health systems face mounting pressure to cut costs without compromising care. The recognition also signals that enterprise integration (not just purchasing efficiency) is what's defining supply chain excellence right now.
Source: Healthcare Purchasing News
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe